<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02254668</url>
  </required_header>
  <id_info>
    <org_study_id>KEK-ZH_Nr. 2012-0409</org_study_id>
    <nct_id>NCT02254668</nct_id>
  </id_info>
  <brief_title>Intracoronary Analysis of Cardiac Allograft Vasculopathy by Means of Optical Coherence Tomography</brief_title>
  <acronym>OCTandCAV</acronym>
  <official_title>Intracoronary Analysis of Cardiac Allograft Vasculopathy in Comparison to Coronary Artery Disease by Means of Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized prospective multi-center imaging study which investigates the impact of different
      immunosuppressive protocols (Everolimus (Certican®) or Mycophenolate mofetil (CellCept®)) on
      cardiac allograft vasculopathy (CAV) in heart transplanted patients. Maximal intima-thickness
      will be visualized by optical coherence tomography (OCT) to assess the progression of CAV.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In summary, the aim of the study is to examine the effect of the immunosuppressive agent
      Everolimus (Certican) on the development of cardiac allograft vasculopathy (CAV).

      Therefore the study is divided in three sections:

      Substudy 1: Evaluation of morphological differences between between CAD and CAV.

      Substudy 2: Analysis of cardiovascular risk factors (e.g. hypertension) under a specific
      immunosuppressive protocol in patients with CAV.

      Substudy 3: Prospective, randomized analysis of the influence of different immunosuppressive
      protocols in patients with CAV.

      Primary endpoint of the study will be the adaption of intimal thickness after 10 years,
      analysed by means of optical coherence tomography.

      In addition to the explanations above the most important in- and exclusion criteria are
      listed below:

      Inclusion Criteria:

        -  Patients after heart transplantation

        -  Patients with coronary artery disease (CAD)

        -  Age 18-80 years

      Exclusion Criteria:

        -  Contraindication of Everolimus/Sirolimus or adjuvants

        -  Renal insufficiency (Creatinine &gt; 265 µmol/l)

        -  Cardiogenic shock or patients with Killip*-Class III or IV (*name)

        -  Pregnant or breast feeding females

        -  insufficient contraception (only for substudy 3)
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intimal Thickness</measure>
    <time_frame>Assessment intervals of patients with CAV is 1 year and 2 years in patients without CAV</time_frame>
    <description>Assessment is usually performed by intracoronary angiography and endomyocardial biopsy which is routinely performed &lt;1 year after heart transplantation. Furthermore, assessment interval will be defined according to the result of these investigational procedures. If there is a diagnosis of CAV the interval will be one year, if not a follow-up examination in two years will be sufficient.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">278</enrollment>
  <condition>Intimal Proliferation</condition>
  <condition>Immunosuppression</condition>
  <arm_group>
    <arm_group_label>Everolimus (Certican®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®). No protocol with Mycophenolate mofetil (CellCept®). Daily dosage administered depending on blood concentration (control interval 6-12 months)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mycophenolate mofetil (CellCept®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®). No protocol with Everolimus (Certican®). Daily dosage administered depending on blood concentration (control interval 6-12 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Protocol with Everolimus (Certican®)</intervention_name>
    <description>Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).</description>
    <arm_group_label>Everolimus (Certican®)</arm_group_label>
    <other_name>Randomizaiton by SecuTrial</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Protocol with Mycophenolate mofetil (CellCept®)</intervention_name>
    <description>Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).</description>
    <arm_group_label>Mycophenolate mofetil (CellCept®)</arm_group_label>
    <other_name>Randomizaiton by SecuTrial</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with heart transplantation

          -  Patient with coronary artery disease

          -  Age between 18 and 80 years

        Exclusion Criteria:

          -  Renal insufficiency (&gt; 265 µmol/l)

          -  Incapability to give informed consent

          -  Cardiogenic shock of patient with KILLIP III or IV

          -  pregnant or breast feeding females

          -  insufficient contraception (only for substudy 3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Templin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Zurich (Switzerland), Division of Cardiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Templin, MD, PhD</last_name>
    <phone>+41 (0)44 / 255 9585</phone>
    <email>christian.templin@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frank Ruschitzka, Professor</last_name>
    <phone>+41 (0)44 / 255 3957</phone>
    <email>frank.ruschitzka@usz.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Division of Cardiology</name>
      <address>
        <city>Zurich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Templin, MD, PhD</last_name>
      <phone>+41 (0)44 / 255 9585</phone>
      <email>christian.templin@usz.ch</email>
    </contact>
    <contact_backup>
      <last_name>Frank Ruschitzka, Professor</last_name>
      <phone>+41 (0)44 / 255 3957</phone>
      <email>frank.ruschitzka@usz.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Templin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.octnews.org</url>
    <description>Informations about Optical Coherence Tomography (OCT)</description>
  </link>
  <link>
    <url>http://www.transplantation.usz.ch/HealthProfessionals/Herztransplantation/Seiten/default.aspx</url>
    <description>Information about heart transplantation at University Hospital of Zurich</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 29, 2013</study_first_submitted>
  <study_first_submitted_qc>September 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2014</study_first_posted>
  <last_update_submitted>September 29, 2014</last_update_submitted>
  <last_update_submitted_qc>September 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intima</keyword>
  <keyword>thickness</keyword>
  <keyword>transplantation</keyword>
  <keyword>cardiology</keyword>
  <keyword>immunosuppression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Immunosuppressive Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

